Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin D (ergocalciferol) is utilized in patients with Acquired Immune Deficiency Syndrome (AIDS) primarily due to scientific rationale rather than tradition. Several studies have demonstrated that individuals with HIV/AIDS frequently exhibit vitamin D deficiency, which is associated with increased risk of bone demineralization, immune dysregulation, and potentially higher rates of disease progression. Vitamin D plays a role in modulating both innate and adaptive immune responses, and deficiency may exacerbate the immune suppression already characteristic of AIDS.

However, while some observational studies suggest that low vitamin D status in HIV-positive patients correlates with worse outcomes, there is limited clinical trial evidence demonstrating that vitamin D supplementation significantly improves immune function or clinical endpoints in AIDS patients. Most of the evidence supports the use of vitamin D to manage or prevent complications such as osteoporosis and osteomalacia, which are more common in this population, particularly in those receiving antiretroviral therapy (ART). There is insufficient evidence to claim that vitamin D supplementation directly treats HIV infection or substantially alters the course of AIDS outside of addressing deficiency and associated bone health issues.

In summary, the use of vitamin D in AIDS is scientifically justified mainly for correcting deficiency and supporting bone health, with only weak evidence for broader immunomodulatory or disease-modifying effects.

More about Vitamin D (ergocalciferol)
More about Acquired Immune Deficiency Syndrome

Other ingredients used for Acquired Immune Deficiency Syndrome

Other health conditions supported by Vitamin D (ergocalciferol)

Products containing Vitamin D (ergocalciferol)